United States · Platforms & data · Benzinga

Why Is Vir Biotechnology Stock Falling Friday?

Published by Benzinga · United States 51 min ago

Detailed summary

Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10…

Read the full article on Benzinga Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)

Also worth reading

Seeking Alpha

Moving iMage Technologies GAAP EPS of $0.02, revenue of $6.1M

The Motley Fool

ADI Global Distribution: 3 Key Takeaways for Long-Term Investors

MarketWatch

Midterm elections provided the hyperscalers with the excuse they needed to cut back on spending, says Jefferies strategist

Investing.com

Thursday’s insider activity: Major buys and sells disclosed

Yahoo Finance

U-wifi Names Charlie Vogt to its Board of Directors

TheStreet